What we do not do ourselves is done by people whose work we know.

Carelane is a platform for clinical studies and registries. Protocol, data capture, analysis and study management sit in one system instead of five; the protocol is held as a structured document from which the case report forms are generated. It is used by pharmaceutical companies, contract research organisations and academic study groups — and by hospitals that want to run studies of their own.

The raw material of any study built on routine care is the patient record, and most of it is prose: discharge letters, pathology reports, imaging findings, scanned faxes. aiomics turns that into structured, coded fields — every value carrying a reference to the sentence it came from. What happens with it afterwards belongs to Carelane: study logic, per-case physician sign-off, audit trail.

A study site can only offer evidence it is able to defend. Traceable provenance for every single value is the precondition for that. Both sides work on it from different ends.

idalab is an independent AI consultancy focused on medicine and the life sciences. The team works for pharmaceutical and biotechnology companies, medical device manufacturers, care providers and investors: analysis pipelines in drug discovery, tools for market access and pricing, the approval pathway for products with an AI component, the assessment of holdings. Advice and building sit in the same hands, so a strategy does not end in a slide deck.

A hospital's AI question is bigger than documentation. The same meetings decide on reading support in radiology, coding, staff scheduling, forecasting and voice assistance, alongside the rules that now apply to products with an AI component. aiomics answers one part of that. idalab answers the question about the whole: what is worth doing, in what order, on what data foundation, and what has to be evidenced towards the regulator.

We have worked with the same team for years. That removes the usual friction between a vendor and a consultancy: shared vocabulary, the same expectation of evidence, no detour through third parties. And because idalab sells no software of its own, its assessment of our platform is as independent as it ought to be.

INCH Health works on the question of why digital medical products convince in a pilot and then fade in daily practice. The team of clinicians and researchers addresses the usual causes — workflows that do not fit the product, participants with different expectations, missing measures, unclear ownership — and works through them in stages: a short readiness assessment, a workshop, then guidance through a full roll-out. Alongside that, INCH brings clinic, research and industry to one table, among other things in a standing forum on patient monitoring.

Roll-out is part of what we deliver. There is an onboarding portal that carries a hospital through the first weeks, and a team that is not only reachable for technical questions but sits on the ward and shows how the tool is used in daily practice. When a group rolls out across many sites at once, or brings a whole bundle of different systems into operation, that is a job of its own with a method of its own. That is when we recommend INCH.

We have known the founder for close to a decade and have followed the work throughout. The team comes out of the clinic, which shows in the questions it asks.